ASP 4132Alternative Names: ASP4132
Latest Information Update: 22 Apr 2015
At a glance
- Originator Astellas Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 01 Mar 2015 Phase-I clinical trials in Lymphoma and Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO)